Caplin Point Laboratories Limited (BOM:524742)
India · Delayed Price · Currency is INR 1,644.60
-5.80 (-0.35%)
At close: Mar 5, 2026
Caplin Point Laboratories Market Cap
Caplin Point Laboratories has a market cap or net worth of 125.01 billion as of March 5, 2026. Its market cap has decreased by -19.21% in one year.
Market Cap
125.01B
Enterprise Value
116.03B
Revenue
20.92B
Ranking
n/a
PE Ratio
20.43
Stock Price
1,644.60
Market Cap Chart
Since February 26, 2002, Caplin Point Laboratories's market cap has increased from 5.60M to 125.01B, an increase of 2,232,599.33%. That is a compound annual growth rate of 51.69%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 4, 2026 | 125.45B | -10.36% |
| Dec 31, 2025 | 139.95B | -26.39% |
| Dec 31, 2024 | 190.12B | 84.60% |
| Dec 29, 2023 | 102.99B | 90.47% |
| Dec 30, 2022 | 54.07B | -16.82% |
| Dec 31, 2021 | 65.01B | 69.50% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| GlaxoSmithKline Pharmaceuticals | 420.53B |
| J. B. Chemicals & Pharmaceuticals | 332.47B |
| AstraZeneca Pharma India | 217.49B |
| Granules India | 137.16B |
| Jubilant Pharmova | 132.60B |
| Rubicon Research | 123.82B |
| CORONA Remedies | 95.72B |
| Viyash Scientific | 87.86B |